A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma

Ítems similars

• Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
  per: Xiaoyan Han, et al.
  Publicat: (2024-05-01)
• A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma
  per: Noa Biran, et al.
  Publicat: (2025-04-01)
• Daratumumab
  per: Vishnu Gopal, et al.
  Publicat: (2020-01-01)
• Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease
  per: Prabha Shrestha, et al.
  Publicat: (2023-12-01)
• Acquired von Willebrand disease associated with smoldering multiple myeloma and hereditary hemorrhagic telangiectasia successfully treated with daratumumab, pomalidomide, and dexamethasone: hitting three birds with one stone? – case report
  per: Lemchukwu Amaeshi, et al.
  Publicat: (2025-02-01)